{
    "pmcid": "10275483",
    "qa_pairs": {
        "How do nanobodies neutralize the SARS-CoV-2 virus according to the paper?": [
            "By binding to the spike protein's receptor-binding domain and blocking the virus-ACE2 interaction.",
            "By binding to the nucleocapsid protein and preventing viral replication.",
            "By targeting the viral RNA and inhibiting its transcription.",
            "By binding to the viral envelope protein and disrupting its structure."
        ],
        "What are the primary advantages of nanobodies over conventional antibodies in the context of SARS-CoV-2 treatment?": [
            "Smaller size, high thermal stability, solubility, ease of genetic engineering, and lower production costs.",
            "Larger size, higher production costs, and limited tissue penetration.",
            "Complex structure, high production costs, and difficulty in genetic engineering.",
            "Limited stability, larger size, and inability to bind to hidden epitopes."
        ],
        "What challenge is associated with targeting intracellular viral components using nanobodies?": [
            "Delivering nanobodies into cells remains a challenge.",
            "Nanobodies are too large to penetrate cell membranes.",
            "Intracellular viral components are resistant to nanobody binding.",
            "Nanobodies degrade rapidly inside cells."
        ],
        "What potential delivery method is mentioned for nanobodies in therapeutic applications against COVID-19?": [
            "Inhalation therapies.",
            "Intravenous injection.",
            "Oral administration.",
            "Topical application."
        ],
        "What production systems are highlighted for nanobody production in the paper?": [
            "Microbial systems like E. coli and yeast.",
            "Mammalian cell cultures and insect cells.",
            "Plant-based systems and cell-free synthesis.",
            "Avian cell lines and amphibian systems."
        ]
    }
}